JP2020002171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002171A5 JP2020002171A5 JP2019166361A JP2019166361A JP2020002171A5 JP 2020002171 A5 JP2020002171 A5 JP 2020002171A5 JP 2019166361 A JP2019166361 A JP 2019166361A JP 2019166361 A JP2019166361 A JP 2019166361A JP 2020002171 A5 JP2020002171 A5 JP 2020002171A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- administered
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 206010019860 Hereditary angioedema Diseases 0.000 claims 13
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022168140A JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US61/929,716 | 2014-01-21 | ||
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US61/944,361 | 2014-02-25 | ||
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| US62/021,397 | 2014-07-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Division JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168140A Division JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020002171A JP2020002171A (ja) | 2020-01-09 |
| JP2020002171A5 true JP2020002171A5 (cg-RX-API-DMAC7.html) | 2020-02-20 |
| JP7164502B2 JP7164502B2 (ja) | 2022-11-01 |
Family
ID=53681890
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Active JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2019166361A Active JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Active JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11084884B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3848057B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6845012B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20220107077A (cg-RX-API-DMAC7.html) |
| CN (2) | CN106132442B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015209481C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016016916B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2937329C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3096798T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA038532B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2856076T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL246864B (cg-RX-API-DMAC7.html) |
| MX (2) | MX387753B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ723369A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3096798T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3096798T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015112578A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA201605342B (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3459564T1 (sl) | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| JP2014506257A (ja) * | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| EP3456744B1 (en) | 2013-01-20 | 2023-03-29 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| CN111704672B (zh) | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| AU2014340450B2 (en) | 2013-10-21 | 2020-05-21 | Takeda Pharmaceutical Company Limited | Assays for determining plasma kallikrein system biomarkers |
| US10101344B2 (en) | 2013-10-21 | 2018-10-16 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| EA038532B1 (ru) * | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| IL295414B1 (en) | 2014-03-27 | 2025-10-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| EP3286226A4 (en) * | 2015-03-30 | 2018-12-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| PL3365685T3 (pl) * | 2015-10-19 | 2021-08-02 | Dyax Corp. | Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| IL265195B2 (en) * | 2016-09-16 | 2025-02-01 | Dyax Corp | Protein biomarkers for diseases related to the activation system |
| IL315175A (en) | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | RNA biomarkers for hereditary angioedema |
| BR112020007405A2 (pt) * | 2017-10-18 | 2020-12-08 | Regenxbio Inc. | Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| JP7727308B2 (ja) | 2017-12-01 | 2025-08-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用 |
| JP7273417B2 (ja) | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| DK3732185T3 (da) | 2017-12-29 | 2025-03-31 | Suzhou Ribo Life Science Co Ltd | Konjugater og fremstilling og anvendelse heraf |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| EP3938404A1 (en) * | 2019-03-14 | 2022-01-19 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| JP7614650B2 (ja) * | 2019-05-24 | 2025-01-16 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | ASSESSMENT PROCEDURE FOR NEPHROTOXICITY. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| ES2227545T3 (es) | 1994-01-11 | 2005-04-01 | Dyax Corporation | Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| DE60333758D1 (de) | 2002-06-07 | 2010-09-23 | Dyax Corp | Prevention und Verringerung von Ischemia |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2005023870A1 (ja) | 2003-09-04 | 2005-03-17 | Riken | ＴＧＦ－β活性化制御領域の切断面を認識する抗体 |
| EP1713929A2 (en) | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| SI2374472T1 (sl) | 2006-03-16 | 2018-11-30 | Dyax Corp., | Sestavki in postopki za zdravljenje oftalmoloških motenj |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| WO2009012571A1 (en) * | 2007-07-20 | 2009-01-29 | Genesys Venture Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| CA2695012A1 (en) | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| CN102264390A (zh) | 2008-07-02 | 2011-11-30 | 新兴产品开发西雅图有限公司 | Il6免疫治疗 |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| SI3459564T1 (sl) | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012151247A2 (en) | 2011-05-02 | 2012-11-08 | Millennium Pharmaceuticals, Inc. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
| ES2732243T3 (es) | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EP3456744B1 (en) | 2013-01-20 | 2023-03-29 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| JP6656926B2 (ja) | 2013-01-20 | 2020-03-04 | ダイアックス コーポレーション | ｐＫａｌ関連疾病の評価、アッセイおよび治療 |
| CN111704672B (zh) | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| AU2014340450B2 (en) | 2013-10-21 | 2020-05-21 | Takeda Pharmaceutical Company Limited | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| IL295414B1 (en) | 2014-03-27 | 2025-10-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| EP3286226A4 (en) | 2015-03-30 | 2018-12-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| BR112019005167A2 (pt) * | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| EP3678553B1 (en) | 2017-09-05 | 2024-05-22 | Sanolla Ltd | Diagnosis of pathologies using infrasonic signatures |
| MX2021002349A (es) | 2018-08-30 | 2021-05-31 | Takeda Pharmaceuticals Co | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. |
| EP3938404A1 (en) | 2019-03-14 | 2022-01-19 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN115297927A (zh) | 2020-01-13 | 2022-11-04 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途 |
-
2015
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 MX MX2016009428A patent/MX387753B/es unknown
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active Ceased
- 2015-01-21 EP EP20209536.0A patent/EP3848057B1/en active Active
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active Active
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en not_active Ceased
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Pending
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
-
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US12384854B2/en active Active
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
- 2024-09-03 JP JP2024151126A patent/JP2024170495A/ja active Pending